Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

ITK inhibitors may effectively treat alopecia areata.

In this clinical study involving individuals with localized alopecia areata, TrA injections were found to significantly outperform MTX, leading to better hair regrowth and higher patient satisfaction, though both treatments had similar mild side effects.

This review discusses the use of methotrexate for pediatric dermatoses and reports increased use in certain conditions like psoriasis, but mainly isolated case reports for others.

This study found that the Transdermal Delivery System efficiently delivers testosterone systemically and showed bioequivalent hormone concentrations to a known topical gel in healthy males.

In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study explored a new treatment approach using 20% TCA application with topical bimatoprost solution for managing alopecia areata of the eyebrows in cases where traditional treatments failed, offering a potential additional option for difficult cases.

The authors concluded that diazoxide reduces undesirable side effects compared to minoxidil while increasing elastic fiber content and decreasing cell number in the aorta, suggesting potential suitability for treating vascular conditions with low arterial elastin and hypertension.

In this study, researchers identified a specific T cell receptor associated with carbamazepine-induced severe cutaneous adverse reactions, demonstrating its potential for therapeutic development in patients with the HLA-B*15:02 genotype.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This review discusses neuroimmune communication in skin disorders and peripheral neuropathic pain, highlighting the complex interactions between sensory neurons and immune cells; it reports no new clinical results but suggests potential future therapies.

This review found that laser-assisted drug delivery in humans was associated with several adverse effects, but no life-threatening events were reported in the studies examined.

This review explores epidermolysis bullosa simplex subtypes caused by mutations in KRT5 or KRT14 and summarizes gene expression patterns and molecular mechanisms, without presenting new experimental results.

This article reviews the latest data on non-invasive body rejuvenation techniques, discussing advancements in filler technology and offering insights into their effectiveness and safety for both practitioners and patients interested in non-surgical procedures.

This review examines advancements in lipid and inorganic nanocarriers, such as liposomes and inorganic nanoparticles, for transdermal drug delivery, noting enhanced absorption and stability but acknowledging that few have reached clinical use.

This study found that microbotox, especially when injected intradermally, effectively reduces enlarged facial pores with higher patient satisfaction and longer-lasting results compared to its topical application after microneedling.

This study reviews the complexities of burn-related skin complications, highlighting postburn pruritus, dyspigmentation, and the risk of malignant ulcers, while offering a framework for evidence-based management through various treatment approaches.

This study found that platelet-rich plasma may improve patient-reported outcomes for scar symptoms like pain and itching at six months, although no significant changes in scar appearance were observed at three months.

This review discusses the use of botulinum toxin for hair and scalp disorders and reports mixed findings, with most studies showing mild or non-significant effects on hair growth.

This source reports that for treating keloids and hypertrophic scars, combination pharmacotherapy targeting multiple sites is generally more effective than using a single drug, though outcomes of individual therapies vary and the development of satisfying treatments is ongoing.

In this narrative review, the authors explored various rehabilitative techniques, including injections and physical therapies, that may enhance aesthetics and psychosocial wellbeing in patients with disabilities, emphasizing a multidisciplinary approach to improve both functional and cosmetic outcomes.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

In this study using a mouse model, the authors reported that the synthetic antioxidant TS-13 effectively inhibited tumor growth comparably to doxorubicin and reduced chemotherapy side effects, such as weight loss, splenotoxicity, and alopecia, more effectively when combined with the cytostatic treatment.

This study reports two cases of alopecia associated with anti-TNF therapy, highlighting a new entity combining features of alopecia areata and psoriatic alopecia.

In this animal study, atorvastatin co-administered with trastuzumab reversed trastuzumab-induced cognitive impairment (chemo-brain) and improved its anti-cancer efficacy without causing hair loss.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

This opinion article reviews various pathways through which onabotulinumtoxinA might work in medical treatments, highlighting applications beyond muscle paralysis, including pain inhibition and potential effects on hair loss and cancer cell apoptosis.

In a study using hairless mice, tranexamic acid was found to ameliorate natural skin aging, with stronger effects observed in female mice compared to males.

This review found insufficient evidence to determine methotrexate's effectiveness for maintaining regrowth in extensive alopecia areata, and suggests its potential role in inducing regrowth when combined with corticosteroids.

In this randomized, controlled, clinical trial, the researchers found that injectable botulinum toxin did not promote hair growth in men with androgenetic alopecia over 12 or 24 weeks, showing no benefit in improving hair density compared to placebo.